<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11898004
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     03
    </month>
    <day>
     18
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     04
    </month>
    <day>
     18
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0091-6749
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       109
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Mar
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of allergy and clinical immunology
     </title>
     <isoabbreviation>
      J. Allergy Clin. Immunol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.
    </articletitle>
    <pagination>
     <medlinepgn>
      539-46
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Vehicle-controlled studies have demonstrated the efficacy and safety of tacrolimus ointment in the treatment of patients with atopic dermatitis (AD).
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      This study was undertaken to compare 0.03% and 0.1% tacrolimus ointment with 1% hydrocortisone acetate ointment in children 2 to 15 years of age with moderate-to-severe AD.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Treatment was twice daily to affected areas for 3 weeks in this multicenter, randomized, double-blind, parallel-group study. The primary endpoint was the modified eczema area and severity index (mEASI) mean area under the curve (mAUC) as a percentage of baseline.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Five hundred sixty patients were randomized and received at least one application of ointment. Discontinuations included 21 of 189 patients from the 0.03% tacrolimus group, 13 of 186 patients from the 0.1% tacrolimus group, and 20 of 185 patients from the hydrocortisone acetate group. The median mEASI mAUC as a percentage of baseline showed 0.03% and 0.1% tacrolimus to be significantly more effective than 1% hydrocortisone acetate (P &lt;.001) and 0.1% tacrolimus to be more effective than 0.03% tacrolimus (P =.006). The mEASI mAUC as a percentage of baseline was 44.8%, 39.8%, and 64.0% for patients who received 0.03% tacrolimus, 0.1% tacrolimus, and 1% hydrocortisone acetate, respectively. Transient skin burning was the only adverse event to show a higher incidence in the tacrolimus treatment groups than in the hydrocortisone acetate group (P &lt;.05). Laboratory parameters showed no treatment differences and no marked changes over time.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Tacrolimus, 0.03% and 0.1%, was significantly more effective than 1% hydrocortisone acetate and 0.1% tacrolimus was more effective than 0.03% tacrolimus in the treatment of moderate-to-severe AD in children. No safety concerns were identified.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Dermatology, Hospital for Skin and Allergic Diseases, University of Helsinki, Helsinki, Finland.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Reitamo
      </lastname>
      <forename>
       Sakari
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Van Leent
      </lastname>
      <forename>
       Edwin J M
      </forename>
      <initials>
       EJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ho
      </lastname>
      <forename>
       Vincent
      </forename>
      <initials>
       V
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Harper
      </lastname>
      <forename>
       John
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ruzicka
      </lastname>
      <forename>
       Thomas
      </forename>
      <initials>
       T
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kalimo
      </lastname>
      <forename>
       Kirsti
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cambazard
      </lastname>
      <forename>
       Frédéric
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Rustin
      </lastname>
      <forename>
       Malcolm
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Taïeb
      </lastname>
      <forename>
       Alain
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gratton
      </lastname>
      <forename>
       David
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sauder
      </lastname>
      <forename>
       Daniel
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sharpe
      </lastname>
      <forename>
       Graham
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Smith
      </lastname>
      <forename>
       Catherine
      </forename>
      <initials>
       C
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Jünger
      </lastname>
      <forename>
       Michael
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       de Prost
      </lastname>
      <forename>
       Yves
      </forename>
      <initials>
       Y
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       European /Canadian Tacrolimus Ointment Study Group
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Clinical Trial, Phase III
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     J Allergy Clin Immunol
    </medlineta>
    <nlmuniqueid>
     1275002
    </nlmuniqueid>
    <issnlinking>
     0091-6749
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Immunosuppressive Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      109581-93-3
     </registrynumber>
     <nameofsubstance>
      Tacrolimus
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-23-7
     </registrynumber>
     <nameofsubstance>
      Hydrocortisone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      53187-58-9
     </registrynumber>
     <nameofsubstance>
      hydrocortisone acetate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Allergy Clin Immunol. 2002 Mar;109(3):401-3
     </refsource>
     <pmid version="1">
      11897982
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="SummaryForPatientsIn">
     <refsource>
      Curr Allergy Asthma Rep. 2002 Jul;2(4):273-4
     </refsource>
     <pmid version="1">
      12044259
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Topical
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dermatitis, Atopic
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hydrocortisone
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunosuppressive Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tacrolimus
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      3
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      4
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      3
     </month>
     <day>
      19
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11898004
    </articleid>
    <articleid idtype="pii">
     S0091674902074572
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

